IntellectSky

Case No 1:22-cv-00964-RMB-MJS2023 Plaintiff and Counter-Defendant: BRISTOL-MYERS SQUIBB CO., Defendant and Counter-Claimant: XSPRAY PHARMA AB Drug Product: Sprycel® Dasatinib Tablet (Applicant: BMS) Dasynoc® dasatinib (Applicant: Xspray )   Patent(s)-in-Suit:   US7491725 (“the ’725 patent”), US8680103 (“the ’103 patent”), and US8242270 (“the ’270 patent”)   FACTUAL AND PROCEDURAL BACKGROUND: ·         Bristol-Meyers Squibb (“BMS”) owns the patents-in-suit and sells Sprycel, a drug used to treat chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. ·         The patents-in-suit claim various crystalline forms of dasatinib. BMS asserts that Xspray filed an ANDA seeking to market a non-crystalline (i.e., amorphous) dasatinib product under the trade name Dasynoc. ·         BMS alleged that it received a ...

Soumya's words,  Hello friends Hope all are keeping well. I know today's post would be bit lengthy but please bear with it as its necessary for those who feel COVID is just a common flu. - ME AND MY BATTLE WITH CORONA- I have written it as battle with CORONA because the fight with CORONA is in no way less than any of the historic battles.....but the only difference between this battle and those battles is that there they fought against a visible enemy knowing their each move and plans but here I had to fight against an invisible enemy without having least knowledge of its plans and moves. So the battle started on 22 nd April 2021. I got mild symptoms of COVID and being a responsible citizen immediately isolated myself from my family, got my RTPCR done. After 2 days got my reports and it was NEGATIVE. There was no limit of my happiness, the feeling that " yes I am away from the cruel clutches of CORONA" . But little did I know that this was just my illusion. T...

  On 3 rd May 2021, NATCO Pharma Limited has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India. Baricitinib in combination with Remdesivir, is used for treatment of COVID-19 positive patients. Summary: In light of the grave and life threatening public health emergency, NATCO Pharma moved before the Controller of Patents for Compulsory License of Drug Baricitinib in India. NATCO seeking the Compulsory License under Section 92(1) with Section 92(3) of The Patents Act, 1970. Facts & Targeted Approach: PATENT: IN270765 (INCYTE/Lilly: Expiry Date: Mar 10, 2029) Patent Covers: Baricitinib Compound & its phosphoric acid salt. CDSCO Approvals: ·          May 07, 2018: For the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more d...

On May 18, 2020 the Indian Patent Office, granted (IN 336998) a patent application of Indian Space Research Organisation (ISRO) for the technique of making moon-like sand. The application was filed by ISRO on May 15, 2014. There are two types of surfaces on Moon. The first is known as Highland and the second type is Mayer.   The Highland covers 83% of the surface which is contains of calcium and aluminium content, more as compared to other minerals. This type of soil has been made and claimed by ISRO. While the Mayer is visible black crater and contains maximum percentage of Iron, Magnesium and Titanium. ISRO’s invention can be used for scientific studies of lunar terrain relating to mobility/ trafficability of rover for scientific explorations or for the study of geo-technical/ mechanical properties of lunar soil for understanding the engineering behavior of lunar regolith or to carry out fundamental research work (theoretical and experimental) to postulate a broad...

Biogen fends off Mylan’s challenge Dimethyl Fumarate, Proprietary molecule of Biogen with brand name as TECFIDERA available as delayed release capsule with two strength 120mg & 240mg. USFDA has approved the New Drug Application (NDA 204063) provides for the use of Tecfidera (dimethyl fumarate) delayed-release capsules, 120 mg and 240 mg, for the treatment of patients with relapsing forms of multiple sclerosis. OB Listed Patents: US7619001 (Expiring Jun 20, 2020) covers Method for treating Multiple Sclerosis using pharmaceutical preparations with an excipient or at least one carrier using fumarates. The fumarates are limited to dimethyl fumarate (DMF), monomethyl fumarate (MMF), or their combination. US8399514 (Expiring Feb 07, 2028) directed to methods of treating patients needing treatment for Multiple Sclerosis (MS). The heart of the treatment, and a requirement of every claim is administering about 480 milligrams (mg) per day of certain fumarates. Id. The fumarates are limi...